explore -WSS

explore

author：comprehensive 2025-10-01 23:57:57 - browse：48189

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Texas board proposes rules on abortion law emergency exemption

entertainment

knowledge

WSS

Medical devices makers are asking for forgiveness, not permission

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Pregnancy ages women, but effects reverse after delivery

CRISPR technology availability, affordability needs to be expanded

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

focus

explore

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Medical leaders decry Supreme Court decision on affirmative action

Chinese researcher claims birth of first gene

Moonlake's readout produced a cash windfall. Risks remain

Diabetes management: Digital health tools fall short, study says

In age of alternative facts, a scholarly course on calling out crap

Medicare Advantage insurers pressure Biden for bigger payments

Trump demands the U.S. pay no more for drugs than other countries … again

Startling documents reveal new facets of Sacklers' opioid empire

hotspot

Startling documents reveal new facets of Sacklers' opioid empire

Health insurers say they are turning to AI to cut costs, improve care

First Opinion Podcast: What happens when kids become caregivers?

Scientists successfully use ultrasound imaging to map brain activity

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Pfizer, Moderna say biotech, pharma drug development is a sprint

focus

entertainment

knowledge

focus